BioSpace

BMS reports liver injury events in lung disease program, with key readout near

Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s program have caused some unease about the drug class.

By BioSpace

1 min read
BMS reports liver injury events in lung disease program, with key readout near
BMS reports liver injury events in lung disease program, with key readout near

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights